Greenleaf Trust Acquires 9,523 Shares of Johnson & Johnson (NYSE:JNJ)

Greenleaf Trust raised its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 10.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 97,477 shares of the company's stock after purchasing an additional 9,523 shares during the period. Greenleaf Trust's holdings in Johnson & Johnson were worth $16,166,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. CORDA Investment Management LLC. lifted its stake in shares of Johnson & Johnson by 1.7% in the 1st quarter. CORDA Investment Management LLC. now owns 207,755 shares of the company's stock worth $34,454,000 after acquiring an additional 3,538 shares during the period. Silverlake Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 3.9% in the 1st quarter. Silverlake Wealth Management LLC now owns 24,618 shares of the company's stock worth $4,083,000 after acquiring an additional 926 shares during the period. Trek Financial LLC lifted its stake in shares of Johnson & Johnson by 90.4% in the 1st quarter. Trek Financial LLC now owns 3,762 shares of the company's stock worth $624,000 after acquiring an additional 1,786 shares during the period. DekaBank Deutsche Girozentrale lifted its stake in Johnson & Johnson by 1.6% during the first quarter. DekaBank Deutsche Girozentrale now owns 4,483,071 shares of the company's stock valued at $731,462,000 after purchasing an additional 71,750 shares during the last quarter. Finally, OMNI 360 Wealth Inc. boosted its holdings in Johnson & Johnson by 57.2% during the first quarter. OMNI 360 Wealth Inc. now owns 5,221 shares of the company's stock worth $866,000 after buying an additional 1,899 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on JNJ. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Barclays reduced their target price on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Royal Bank Of Canada restated an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Thursday, June 5th. Bank of America reduced their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a report on Thursday, April 10th. Finally, Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Eleven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average price target of $171.00.

Johnson & Johnson Stock Down 0.5%

JNJ stock traded down $0.82 during midday trading on Friday, reaching $156.87. The company had a trading volume of 7,866,488 shares, compared to its average volume of 8,077,942. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $377.44 billion, a P/E ratio of 17.45, a PEG ratio of 2.14 and a beta of 0.41. The company has a 50 day moving average of $153.75 and a two-hundred day moving average of $154.55.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. On average, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.31%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.